Strides Pharma gets another EIR for Bengaluru facility

Strides Pharma Science Limited has received an establishment inspection report (EIR) for the inspection conducted by United States Food & Drug Administration (USFDA) in January 2020 at its flagship facility (KRS Gardens) in Bengaluru thereby, confirming the successful closure of the inspections.

The inspection was related to specific extended release applications made from the site.

The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage formulation products across multiple dosage formats including tablet, capsules, ointments, creams and liquids. The facility is also capable of manufacturing complex formulations of extended release tablets, which is one of the core focus area of the company. The company has a large extended release portfolio for US and other regulated markets with a capability of manufacturing these products at multiple sites.

Last week, it had also received an EIR for Bengaluru facility from USFDA for the inspection conducted in March 2020.

Strides Pharma operates in the regulated markets and has an ‘in Africa for Africa’ strategy along with an institutional business to service donour-funded markets. The company’s global manufacturing sites are located in India-Bengaluru (two locations), Pondicherry and Chennai, Singapore, Milan (Italy), Nairobi (Kenya) and Florida (United States).

On Monday, the stock of Strides Pharma opened gap up 5.2 per cent at Rs 324 from its previous close of Rs 308 on BSE.